Trial intelligence / Profile preview

DermaVir in Treatment-Naïve HIV-1

NCT00711230Phase 2Completed

Sponsor
Genetic Immunity
Start
Apr 2008
Primary completion
Dec 2011
Modality
Nanoparticles, DNA Therapeutics, Vaccines & Immunotherapeutics
Countries
1
01

Overview

A Phase 2 trial of DermaVir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Genetic Immunity. Started Apr 2008; status: completed.

02

Drugs

DermaVir
03

Conditions

human immunodeficiency virus type 1 infection (HIV-1)

Beyond the preview

Go deeper on NCT00711230.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00711230.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call